Maravai LifeSciences (NASDAQ:MRVI) Releases Earnings Results, Beats Estimates By $0.03 EPS

Maravai LifeSciences (NASDAQ:MRVI) issued its quarterly earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03, FiscalAI reports. Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The business had revenue of $49.87 million during the quarter, compared to the consensus estimate of $49.06 million.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• The company returned to positive adjusted EBITDA in Q4 with $0.536M, exceeded its cost-savings target (now > $65M annualized), and made a voluntary $50M debt repayment in Q1 2026 to reduce interest expense.
• 2026 guidance targets meaningful improvement — revenue of $200M–$210M (up 8%–13%) and adjusted EBITDA of $18M–$20M, with forecasted ~1,200 bps gross margin expansion and ~13% lower operating expenses.
• Commercial and product momentum at TriLink and Cygnus — strong demand for GMP consumables and CDMO services, early traction for ModTail and mRNA Builder, > $1.2M of GMP enzyme orders in hand for 2026, and Cygnus’s high-margin HCP kits plus growing MockV/MachV services expanding analytical offerings.
• GAAP results remain weak due to non-cash charges — Q4 GAAP net loss was $63M (including a $25.8M intangible impairment and $12.1M restructuring), full-year GAAP loss $230.8M, and Q4 operating cash outflow was $22.8M, with long-term debt of $294.2M before the voluntary repayment.

Maravai LifeSciences Stock Performance

Shares of MRVI traded up $0.31 during trading hours on Thursday, reaching $3.57. 3,499,380 shares of the company traded hands, compared to its average volume of 1,116,594. Maravai LifeSciences has a 1-year low of $1.66 and a 1-year high of $4.11. The stock has a market cap of $911.61 million, a P/E ratio of -4.24 and a beta of 0.39. The stock’s fifty day moving average is $3.43 and its 200 day moving average is $3.19. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29.

Insider Buying and Selling

In related news, Director Gregory T. Lucier acquired 51,472 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were bought at an average cost of $3.70 per share, with a total value of $190,446.40. Following the completion of the acquisition, the director owned 106,595 shares of the company’s stock, valued at $394,401.50. This trade represents a 93.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.11% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Several large investors have recently made changes to their positions in the company. Quantessence Capital LLC bought a new stake in Maravai LifeSciences during the 3rd quarter worth approximately $31,000. CIBC Bancorp USA Inc. acquired a new position in Maravai LifeSciences in the third quarter worth $33,000. Abel Hall LLC bought a new stake in shares of Maravai LifeSciences during the third quarter worth $33,000. Insigneo Advisory Services LLC acquired a new stake in shares of Maravai LifeSciences in the fourth quarter valued at $34,000. Finally, Virtu Financial LLC acquired a new stake in shares of Maravai LifeSciences in the fourth quarter valued at $34,000. Institutional investors own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company upped their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.25.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.